Directional and Balancing Selection on Proprotein Convertase Subtilisin/Kexin Type 6 (PCSK6)

doi 10.7287/peerj.preprints.2141
Full Text
Abstract

Available in full text

Date
Authors
Publisher

PeerJ

Related search

PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2017English

Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Clinical Research in Cardiology Supplements
Nuclear MedicineRadiologyMolecular BiologyStructural BiologyImagingMedicine
2019English

Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

Variations of the Proprotein Convertase Subtilisin/Kexin Type 9 Gene in Coronary Artery Disease

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2009English

Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK-9) Inhibitors Induced Liver Injury - A Retrospective Analysis

Journal of Community Hospital Internal Medicine Perspectives
Internal Medicine
2020English

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9

Pharmacological Reviews
Molecular MedicinePharmacology
2016English

Fasting Reduces Plasma Proprotein Convertase, Subtilisin/Kexin Type 9 and Cholesterol Biosynthesis in Humans

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy